the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
Published 7 days ago • 70 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:22
safety and efficacy of cc-99282 in the treatment of r/r nhl
-
4:43
phase ib trial of ianalumab plus ibrutinib for cll
-
1:25
the management of cll in italy
-
37:09
yale20 - hematology emergencies
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
6:23
fc bridged cell-mediated cytotoxicity
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
0:47
preliminary safety and efficacy of enitociclib in patients with nhl & cll
-
1:08
overview of the phase i study with acalabrutinib (acp-196) in cll
-
3:17
transcend-cll-004 study update: safety and efficacy of liso-cel in r/r cll
-
2:41
safety and efficacy of actaly-cel™ in r/r pediatric b-all
-
2:25
monitoring infection risk in patients with cll & insights into the prevent-acall trial
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
2:08
an insight into the current understanding of risk factors for cll
-
1:01
investigating the safety profile of enitociclib in patients with high-risk cll & richter's syndrome
-
1:33
key factors affecting treatment decision making in cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
3:02
real-world safety and efficacy of cilta-cel in r/r multiple myeloma
-
2:36
treatment approaches to cll with high-risk molecular features